News

The study, conducted with a new class of antibiotics designed to inhibit staphylococcal fatty acid biosynthesis by means of a new drug target, the fatty acid synthase II

ABP said its patented Accu-Break tablets can be split easily by hand into exact smaller doses, which will make it easier and safer for patients and caregivers to

The Phase 2 study will enroll approximately 20 patients who will receive etirinotecan pegol once every three weeks as monotherapy. Stanford Cancer Institute professor of neurology and neurosurgery,

As a part of the collaboration, Gallus will provide process development and clinical and commercial supply for mammalian cell-based biopharmaceutical products to Theorem’s customers. Theorem will provide contract

The grant will allow analyzing the human genome comprehensively to find additional genetic predispositions to developing COPD in the COPDGene Study. The COPD Foundation president and co-founder John

Spring Point Project’s team has experience under the current Good Manufacturing Practices required by US Food and Drug Administration regulations. Islet Sciences chairman and CEO John Steel said

Under the license agreement, Pfizer will have the exclusive rights to market and sell EpiPen Injection 0.3/0.15mg in Japan, which is the only approved epinephrine auto-injector in the

Cellceutix chief scientific officer Krishna Menon said to date, everything is completed and Cellceutix is waiting for the host hospitals to begin dosing patients, which the company anticipates

The approved product is the generic version of Hospira’s Amidate injection, used as intravenous injection for the induction of general anesthesia. Mylan at present has 169 ANDAs pending